Subcutaneous · GLP-1 / glucagon dual
Efinopegdutide
15 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
15
Active
1
Recruiting
0
Completed
12
Sites
336
Countries
34
Endpoints
244
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
9
Phase 2
6
Trials by status
Active, not recruiting
1
Completed
12
Terminated
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
151
Cardiometabolic biomarkers
36
Weight & body composition
23
Glycemic / diabetes
19
MASH / liver
14
Other (unclassified)
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
AUC₀–∞Safety/PK
25
Treatment-emergent AEs (any)Safety/PK
19
CmaxSafety/PK
15
TmaxSafety/PK
12
Half-lifeSafety/PK
11
Discontinuation due to AESafety/PK
9
Body weight, absolute change (kg)Weight
8
Body weight, % changeWeight
8
Immunogenicity (ADA)Safety/PK
7
Plasma concentration (steady state)Safety/PK
5
HDL-C, changeBiomarker
5
LDL-C, changeBiomarker
5
Total cholesterol, changeBiomarker
5
Triglycerides, changeBiomarker
5
Liver fat content, changeMASH
5
Fasting glucose, changeGlycemic
4
Heart rate, changeBiomarker
3
≥5% weight-loss respondersWeight
3
Non-HDL cholesterol, changeBiomarker
2
ApoB, changeBiomarker
2
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
15 of 15